AI Article Synopsis
- The standard of care for Type 1 diabetes (T1D) has not significantly changed since the 1920s, relying mainly on various insulin types to manage symptoms without addressing the root cause, the autoimmune response.
- There is a pressing need for new treatment options that target both the symptoms and the underlying immune issues associated with T1D.
- Progress towards effective therapies in humans could hinge on using biomarkers in clinical trials, which may help establish a new standard of care that tackles autoimmunity alongside symptom management.
Article Abstract
The standard of care (SoC) for Type 1 diabetes (T1D) today is much the same as it was in the early 1920s, simply with more insulin options-fast-acting, slow-acting, injectable, and inhalable insulins. However, these well-tolerated treatments only manage the symptoms and complications, but do nothing to halt the underlying immune response. There is an unmet need for better treatment options for T1D that address all aspects of the disease. For decades, we have successfully treated T1D in preclinical animal models with immune-modifying therapies that have not demonstrated comparable efficacy in humans. The path to bringing such options to the clinic will depend on the implementation and standard inclusion of biomarkers of immune and therapeutic efficacy in T1D clinical trials, and dictate if we can create a new SoC that treats the underlying autoimmunity as well as the symptoms it causes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clim.2015.05.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Positive correlation between n-6 : n-3 PUFA ratio intake with serum oxHDL/HDL-c ratio in patients with coronary artery disease.
Coron Artery Dis
October 2024
Departamento de Biología Molecular y Genómica, Instituto de Nutrigenética y Nutrigenómica Traslacional.
Background: Coronary artery disease (CAD) is one of the most prevalent cardiovascular diseases where serum lipoprotein oxidation plays a significant role. Polyunsaturated fatty acids (PUFA) n-6 : n-3 unbalance ratio consumption, affects lipoprotein oxidation, and inflammation processes. This study aimed to analyze the relationship between n-6 : n-3 PUFA ratio intake with oxidized lipoproteins in individuals with CAD.
View Article and Find Full Text PDFDeterminants and prevalence of metabolic syndrome among the adult population in Hargeisa, Somaliland: A community-based cross-sectional study.
PLoS One
December 2024
Department of Nutrition, Addis Ababa Medical University College Hargeisa Campus, Hargeisa, Somaliland.
Background: Metabolic syndrome (met-s) is a medical condition that includes abdominal obesity, hyperlipidemia, high blood glucose, and high blood pressure. It is associated with a high risk of developing cardiovascular diseases and type 2 diabetes mellitus. The condition was believed to be a challenge mostly faced by developed nations.
View Article and Find Full Text PDFKidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk.
Clin J Am Soc Nephrol
October 2024
OptumLabs, Eden Prairie, Minnesota.
Evaluation of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis, Omentin, and Tumor Necrosis Factor-α in Subjects with Periodontitis and Type 2 Diabetes Mellitus.
Genet Test Mol Biomarkers
December 2024
SRM Dental College, Bharathi Salai, Chennai, India.
Periodontal disease worsens glycemic control due to the bidirectional link between periodontitis and type 2 diabetes mellitus (T2DM), involving inflammatory markers such as soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK), tumor necrosis factor-α (TNF-α), and omentin-1. However, their combined role in T2DM with periodontitis has not been studied. This study aimed to evaluate the levels of these biomarkers in periodontitis patients with T2DM before and after nonsurgical periodontal therapy (NSPT).
View Article and Find Full Text PDFBolanthus turcicus: a promising antidiabetic with in-vitro antioxidant, enzyme inhibitory and antiadipogenic activities.
J Mol Histol
December 2024
Complementary and Integrative Medicine, Department of Traditional, Ankara Yıldırım Beyazıt University, Ankara, Türkiye, Turkey.
It is crucial to investigate new anti-diabetic agents and therapeutic approaches targeting molecules in potential signaling pathways for the treatment of Type 2 diabetes mellitus (T2DM). The objective of the study was to investigate the total phenolic content, antioxidant capacity, α-glucosidase, and α-amylase inhibitory activities of Bolanthus turcicus (B. turcicus), as well as their cytotoxic, anti-adipogenic, anti-diabetic, apoptotic, and anti-migration potential on adipocytes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!